Vanda Pharmaceuticals Inc. (VNDA)

NASDAQ: VNDA · IEX Real-Time Price · USD
6.29
+0.17 (2.86%)
Jul 22, 2024, 1:21 PM EDT - Market open
2.86%
Market Cap 359.08M
Revenue (ttm) 177.60M
Net Income (ttm) -4.89M
Shares Out 58.20M
EPS (ttm) -0.09
PE Ratio n/a
Forward PE 30.30
Dividend n/a
Ex-Dividend Date n/a
Volume 287,533
Open 6.11
Previous Close 6.11
Day's Range 6.06 - 6.31
52-Week Range 3.30 - 6.75
Beta 0.75
Analysts Buy
Price Target 11.00 (+75.02%)
Earnings Date Jul 29, 2024

About VNDA

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bi... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 12, 2006
Employees 203
Stock Exchange NASDAQ
Ticker Symbol VNDA
Full Company Profile

Financial Performance

In 2023, VNDA's revenue was $192.64 million, a decrease of -24.27% compared to the previous year's $254.38 million. Earnings were $2.51 million, a decrease of -60.02%.

Financial Statements

Analyst Forecast

According to one analyst, the rating for VNDA stock is "Buy" and the 12-month stock price forecast is $11.0.

Price Target
$11.0
(75.02% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex

WASHINGTON , July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of Delaware (the "Court") denied the motions f...

21 days ago - PRNewsWire

Future Pak withdraws offer to buy Vanda Pharmaceuticals

Contract manufacturer Future Pak said on Wednesday it has withdrawn its offer to acquire Vanda Pharmaceuticals , citing non-engagement from the U.S. drugmaker.

25 days ago - Reuters

Future Pak Withdraws Proposal to Purchase Vanda Pharmaceuticals Inc.

WIXOM, Mich.--(BUSINESS WIRE)--Consistent with the position indicated in its June 13, 2024 letter to Vanda Pharmaceuticals (“Vanda”), Future Pak LLC and its affiliates ("Future Pak") today announced t...

25 days ago - Business Wire

Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Thursday.

4 weeks ago - Benzinga

Vanda rejects Future Pak and Cycle Pharma's takeover offers

Vanda Pharmaceuticals said on Wednesday that it has rejected takeover offers from UK-based Cycle Pharmaceutical and a revised bid from contract manufacturer Future Pak, adding that both offers underva...

4 weeks ago - Reuters

Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders

WASHINGTON , June 19, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Company's Board of Directors (the "Board"), following careful review and consultat...

4 weeks ago - PRNewsWire

Global Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98%

The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size is Expected to Reach USD 6.47 Billion by 2033, according to a research report...

5 weeks ago - GlobeNewsWire

Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak

No Shareholder Action Required at This Time WASHINGTON , June 13, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it has received a revis...

5 weeks ago - PRNewsWire

Future Pak raises cash portion of buyout offer for Vanda

Contract manufacturer Future Pak said on Thursday it has raised the cash portion of its buyout offer as part of a final attempt to acquire Vanda Pharmaceuticals.

5 weeks ago - Reuters

Future Pak Issues Enhanced and Final Proposal to Acquire Vanda Pharmaceuticals Inc.

WIXOM, Mich.--(BUSINESS WIRE)--Future Pak, LLC and its affiliates ("Future Pak") today announced that it has submitted a final attempt to engage with Vanda Pharmaceuticals Inc. ("Vanda" or the "Compan...

5 weeks ago - Business Wire

CIONIC Unveils Three New Centers of Excellence on the East Coast to Aid Patient Mobility Through the Use of FDA-Cleared Bionic Clothing and Neuromodulation

SAN FRANCISCO--(BUSINESS WIRE)-- #assistivetechnology--CIONIC Unveils Three New Centers of Excellence to Aid Patient Mobility Through the Use of FDA-Cleared Bionic Clothing and Neuromodulation.

Other symbols: ICCH
6 weeks ago - Business Wire

Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) concerning the Company and its directors' and officers' possible...

6 weeks ago - Business Wire

Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.

No Shareholder Action Required at This Time WASHINGTON , June 6, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it has received an unsol...

6 weeks ago - PRNewsWire

Vanda Pharmaceuticals stock: why is it up 20% on Thursday?

Vanda Pharmaceuticals Inc (NASDAQ: VNDA) is up nearly 20% on Thursday following a report that Cycle Pharmaceuticals Ltd is interested in taking over the Washington-based company.  Vanda Pharmaceutical...

6 weeks ago - Invezz

Cycle Pharmaceuticals Announces All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share

BOSTON & CAMBRIDGE, England--(BUSINESS WIRE)--Cycle Pharmaceuticals Ltd (“Cycle” or the “Company”), a rapidly growing pharmaceutical company focused on treatments for the underserved rare disease pati...

6 weeks ago - Business Wire

Vanda Insights: Aramco share sale is not surprising

Vandana Hari, founder of Vanda Insights, says it'll be a "test of investor appetite."

7 weeks ago - CNBC International TV

Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference

WASHINGTON , May 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2024 Global Healthcare Conference in New ...

7 weeks ago - PRNewsWire

Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®

WASHINGTON , May 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that ownership of the U.S. New Drug Application and Investigational New Drug Applications fo...

7 weeks ago - PRNewsWire

Vanda Pharmaceuticals Announces Presentations at SLEEP 2024

WASHINGTON , May 29, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2024, to be held in Houston, TX from June 1 through June 5, 2024. The...

7 weeks ago - PRNewsWire

Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its Shareholders

WASHINGTON , May 24, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Company's Board of Directors (the "Board") carefully reviewed the revised unsolicit...

2 months ago - PRNewsWire

Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness

•         New Drug Application expected to be submitted in Q4 2024 WASHINGTON , May 15, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the results from its seco...

2 months ago - PRNewsWire

Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results

Revenues for Q1 2024 were $47.5 million, an increase of 5% compared to Q4 2023 Cash increase of $5.9 million in Q1 2024 to $394.1 million Fanapt® approved for the acute treatment of bipolar I disorder...

2 months ago - PRNewsWire

Future Pak Increases Bid for Vanda Pharmaceuticals to Include CVRs in Addition to $7.25 to $7.75 Per Share in Cash

WIXOM, Mich.--(BUSINESS WIRE)--Future Pak LLC (“Future Pak”) confirms it increased its offer for all outstanding shares of common stock of Vanda Pharmaceuticals (“Vanda” or “the Company”) (NYSE: VNDA)...

2 months ago - Business Wire

Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024

Conference Call and Webcast to Follow WASHINGTON , April 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2024 o...

2 months ago - PRNewsWire

Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer

Investment firm Shareholder Capital sent a letter to drugmaker Vanda Pharmaceuticals' board on Thursday asking it to reconsider Future Pak's takeover offer.

3 months ago - Reuters